Patient Materials

OCREVUS IV Welcome Booklet

This material can be provided to people with multiple sclerosis who have been prescribed OCREVUS IV, containing an overview of their condition, how OCREVUS IV works, as well as information to help them process their diagnosis and treatment.

Please download the material here.

Download

OCREVUS SC Welcome Booklet

This material can be provided to people with multiple sclerosis who have been prescribed OCREVUS SC, containing an overview of their condition, how OCREVUS SC works, and information to help them process their diagnosis and treatment.

Please download the material here.

Download

OCREVUS Switch Booklet

For patients with multiple sclerosis who have been receiving OCREVUS IV infusions and who will now be switching to OCREVUS SC. The booklet aims to reassure and inform these patients by outlining what happens during the treatment, what to expect, and how to look after themselves on injection days and beyond.

Please download the material here.

Download

Reference:
1. OCREVUS IV Summary of Product Characteristics (SmPC)

2. OCREVUS SC Summary of Product Characteristics (SmPC)

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

Adverse reactions should be reported by brand name and batch number.